OpenLobby.EU
Explore

Fundación Centro Tecnolóxico de Telecomunicacións de Galicia

GRADIANT

Gradiant’s main goal is to contribute to the competitiveness and growth of the ICT industry in our region Galicia, Spain and the EU through excellence in research and technological development, and technology transfer to industry and society.

Lobbying Activity

Response to EU quantum Act

5 Dec 2025

At Gradiant, a Spanish RTO, we are at the forefront of the development of new comprehensive quantum technology-based solutions. We combine a high level of expertise in quantum physics and photonics with our traditional strengths in electronics, radio frequency engineering, FPGA programming, artificial intelligence, cryptography and software development. Below are our recommendations for the EU Quantum Act based on our experience, with particular emphasis on quantum sensing and communication. Quantum Sensing: With the Quantum Act, Europe should seek to solidify its leadership in quantum sensing, moving from lab-scale sensing applications to sovereign, system-ready solutions. This includes promoting coordinated investment in full-stack development processes to reduce dependency on external markets and non-EU commercial partners. Examples include materials, device packaging, and AI-driven signal processing. This will imply reinforcing the activity of established research groups and integrators in the EU, avoiding effort duplication across Member States and dispersion. In order to create immediate market pull and dual-use capabilities, scaling calls for a dedicated European Quantum Sensing Flagship, mandatory modularity and ruggedisation standards in funded projects, and cross-sector pilot programmes that pair innovators with strategic industries (healthcare, energy, and aerospace). Quantum Communications: The EU's Quantum Act should prioritise the scaling up of secure and trustworthy communications leveraging quantum applications. This means to foster the deployment of end-to-end QKD lines for terrestrial and satellite networks, enabling safe information exchange among more than two users at the same time and incorporating quantum security into traditional infrastructures like 5G/6G and OpenRAN. Equally important, the Quantum Act should support research on multi-user protocols and enabling devices like quantum memories and repeaters, and the integration of proof of concepts for quantum networks is necessary. The interconnection amongst quantum communication and computing devices shall be enabled by novel wavelength transceivers. To secure Europe's place in the world of quantum connectivity, this calls for interoperability standards, strategic procurement by public institutions as early adopters, targeted investment in space-qualified components, and industrial partnerships to guarantee a quick transition to quantum-safe networks.
Read full response

Response to Europe’s Beating Cancer Plan

2 Mar 2020

The ideas of this feedback stem from the work being carried out within the H2020 project PERSIST (https://cordis.europa.eu/project/id/875406) coordinated by our entity and focused on improving the care of cancer survivors. We believe that quality of life and care of cancer survivors must be given special prominence within the Europe's Beating Cancer Plan, as the percentage of population under this category is expected to grow progressively. Survivor quality of life is affected by irreversible toxicities of treatment. The long-term side effects are different for survivors and become the heaviest burden for them even making impossible to return to work. Moreover many survivors remain unaware of their risk of recurrence and late effects, ignoring that optimal lifestyle after diagnosis contributes to the recovery and reduces the risk of second primary tumours. In fact, in many forms of cancer, being a survivor implies accepting a modified nature of one's own body which can lead to forms of psychological and cognitive blockages to the point of generating the inability to be autonomous. This kind of blockages can unfairly affect already vulnerable groups such as women. Prevention: Initiatives like PERSIST provide an example of how prevention can be supported in two ways: easing data from cancer patients in order to have a more accurate prevention of the leading causes of the disease (through data analytics and correlating different data sources (localization data, environmental data, habits etc); and contribution to an exhaustive monitoring of cancer survivors in avoidance of possible relapses or secondary tumours. Early detection and diagnosis: Possible instruments that facilitates the early detection and diagnosis are tools such as those related with differential diagnosis with allow to distinguish a particular disease from others with similar clinical features. To develop such systems structured data is an essential requirement which is not always fulfilled. Electronic Health Records (EHR) contain extensive information about patients, ranging from symptoms to medicines and surgeries. These registries constitute a rich source of data to train artificial intelligence models capable of cancer early detection. Unfortunately, most of times data is available as free text, and techniques such as Natural Language Processing are required even though they are not fully developed for all the languages present in the EU. Treatment and care: It is relevant also to remark on the relevance of tools for supporting the tracking of cancer survivor's mood swings during the treatment providing to patients a clear image of their progress and allowing clinicians to have a better monitoring of the patient’s physical and mental status. Other interesting AI tools are the disease trajectories, which represent the evolution of the patient from the diagnosis of the disease, and the events trajectories which identify associations between symptoms and events (admission, readmissions, treatments, etc.) and can be used to quantify risks. Both of these tools can allow to detect common patient evolutions and choose the more suitable treatment and care based on what was more effective for other similar patients. Quality of life for cancer patients, survivors and carers: Platforms as CDSS (Clinical Decision Support Systems), comparable to PERSIST, combining data from different sources will support the design of survivorship care plans (SCPs) and continually review and update them based on risks and adapted to the patients’ needs. The application of the CDSS enables a patient-centred approach which makes available data for providing assistance, with clinical decision-making, to clinical professionals in the development, personalisation and update of personalised survivorship care plans.
Read full response